MDACC Study No:2008-0841 ( NCT No: NCT00823719)
Title:A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem
Cell Transplantation
Principal Investigator:Alma [Lymphoma - VP Medical Affairs] Rodriguez
Treatment Agent:Carboplatin; Chemotherapy; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Ifosfamide; Ofatumumab
Study Status:Terminated
Study Description:The goal of this clinical research is to learn if ofatumumab given in
combination with a routine chemotherapy treatment can help to control the
disease in patients with certain types of lymphoma. Ofatumumab will be studied
in combination with ifosfamide, carboplatin, etoposide (ICE) and in combination
with dexamethasone, cytarabine, and cisplatin (DHAP). The safety of these drug
combinations will also be studied.

At M. D. Anderson, ICE chemotherapy is standard of care. For this reason,
participants at M. D. Anderson will be receiving ofatumumab in combination with
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Carboplatin
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:NA
Supported By:GlaxoSmithKline
Return Visit:Patient will need to come to the hospital to have treatment for up to 5 days
every 3 weeks.
Home Care:NA

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Alma [Lymphoma - VP Medical Affairs] Rodriguez
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults